Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tam, C
Right arrow Articles by Grigg, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tam, C
Right arrow Articles by Grigg, A.
Haematologica, Vol 90, Issue 5, 700-702
Copyright © 2005 by Ferrata Storti Foundation

Comparative Study

Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies

C Tam, JF Seymour, M Brown, P Campbell, J Scarlett, C Underhill, D Ritchie, R Bond, and AP Grigg

Whether the addition of rituximab to fludarabine and cyclosphosphamide (FC) increases early or late infection risk remains poorly defined. This retrospective analysis of 160 patients treated with FC+/-rituximab found no evidence of increased infection among patients receiving FC+rituximab, providing some evidence of safety for the continued exploration of this regimen.


This article has been cited by other articles:


Home page
 BloodHome page
C. S. Tam and J. F. Seymour
The infectious consequences of rituximab addition to fludarabine-containing regimens.
Blood, April 1, 2006; 107(7): 3013 - 3014.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.